Wegovy (semaglutide) is an FDA-approved once-weekly GLP-1 injection indicated for chronic weight management in adults with obesity or overweight with a weight-related condition, and to reduce major cardiovascular event risk in adults with established cardiovascular disease and obesity or overweight. In the STEP 1 trial, adults taking Wegovy for 68 weeks achieved an average body-weight reduction of 14.9%, compared with 2.4% with placebo.
What happens after the early weight loss is often the harder question. Wegovy can support long-term weight management, but it isn't a short course that guarantees permanent results, and choosing it requires more than looking at a number on a scale. Your medical history, current medicines, symptoms, cardiovascular risk, treatment goals, and plan for ongoing care all matter.
Table of Contents
- What Wegovy Is and Why This Guide Exists
- How Wegovy Works and What the FDA Label Approves
- What the Clinical Trials Show
- Who May Be a Candidate, and Who Should Avoid It
- Comparing Wegovy With Other GLP-1 and Incretin Medicines
- Side Effects, Safety Signals, and Routine Monitoring
- Sustaining Weight Management After Starting Wegovy
- Cost, Coverage, and Practical Questions
What Wegovy Is and Why This Guide Exists
Wegovy contains semaglutide, a medication in the GLP-1 receptor agonist class. GLP-1 is a hormone involved in appetite, digestion, and blood-glucose regulation. Wegovy is used with a reduced-calorie diet and increased physical activity, not as a replacement for either one.
The FDA approves Wegovy for chronic weight management in certain adults with obesity or overweight. “Chronic” means the treatment is considered part of long-term care rather than a temporary course taken until a target is reached. The FDA label also includes a cardiovascular indication for certain adults with established cardiovascular disease and obesity or overweight, which gives the medication a role beyond weight change alone. The current FDA prescribing information defines the cardiovascular risk reduction as lowering the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in the qualifying population.
The United States approved Wegovy on June 4, 2021, marking a major milestone for prescription obesity treatment. The FDA approval announcement and STEP 1 results helped establish semaglutide as one of the first widely adopted medicines to produce double-digit average weight loss in a large randomized obesity trial.
This guide focuses on what Wegovy is, who may qualify under the FDA label, what the clinical evidence can and can't tell you, and why maintenance planning deserves attention before treatment begins. It isn't a promise of results, a substitute for an evaluation, or a reason to obtain medication outside appropriate medical care. Adults considering physician-led obesity medicine care can use these topics to prepare more useful questions for a licensed prescriber.
How Wegovy Works and What the FDA Label Approves
Semaglutide mimics the activity of GLP-1, an intestinal hormone that communicates with several systems involved in eating and metabolism. In practical terms, it can reduce appetite and food intake, slow the movement of food through the stomach, and improve blood-glucose regulation. It doesn't directly “burn fat.” Its effect is better understood as changing appetite and metabolic signaling so that maintaining a reduced-calorie eating pattern may become more manageable for some people.
Wegovy is administered as a once-weekly subcutaneous injection, meaning it's injected under the skin. The FDA-approved injection is increased gradually, with the labeled maintenance dose reaching 2.4 mg. Gradual escalation is intended to improve tolerability, but it doesn't eliminate nausea or other adverse effects. A prescriber may need to assess tolerance before making any change.
Two approved roles for the same medicine
The first FDA-approved role is chronic weight management. For adults, the label uses a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related condition. Examples include hypertension, abnormal blood lipids, type 2 diabetes, or obstructive sleep apnea. BMI is a screening measure, not a complete description of health, body composition, or treatment need.
The second role is cardiovascular risk reduction. Wegovy is indicated for adults with established cardiovascular disease who also have obesity or overweight. In this setting, the prescribing conversation may include prior cardiovascular events or diagnoses, current prevention treatment, blood pressure, glucose, lipid levels, and the person's broader risk profile. The purpose isn't only to change body weight.
Wegovy, Ozempic, and Rybelsus all contain semaglutide, but their approved indications, formulations, and labeled dosing differ. Empire's semaglutide information can provide general context, but only a licensed prescriber can determine whether a particular product fits a person's medical situation.
What the Clinical Trials Show
How much weight did participants lose in controlled studies, and what can those results tell someone considering long-term treatment?
Wegovy's evidence comes from several randomized, placebo-controlled trials, not one isolated result. In STEP 1, adults treated for 68 weeks had an average body-weight reduction of 14.9%, compared with 2.4% with placebo. At least 5% weight loss occurred in 83.5% of participants receiving Wegovy and 31.1% receiving placebo, as reported in the FDA approval evidence summary.
The FDA reviewed three 68-week randomized, double-blind, placebo-controlled trials and a 68-week withdrawal trial. Across these studies, average placebo-adjusted weight reduction ranged from 6.2 to 12.4 percentage points. The share reaching at least 5% weight loss ranged from 67.4% to 84.8% with Wegovy and 30.2% to 47.8% with placebo. The FDA label also describes a controlled adolescent trial with clinically and statistically significant BMI reductions compared with placebo.
Key Wegovy clinical trial outcomes at a glance
| Trial or evidence set | Population | Duration | Average weight change vs. placebo |
|---|---|---|---|
| STEP 1 | Adults with obesity or overweight without diabetes in the primary trial | 68 weeks | 14.9% with Wegovy versus 2.4% with placebo |
| STEP program reviewed by the FDA | Adults across multiple controlled studies | 68 weeks | Placebo-adjusted reduction ranged from 6.2 to 12.4 percentage points |
| STEP 5 | Adults with overweight or obesity | 104 weeks | 15.2% with Wegovy versus 2.6% with placebo |
Duration matters because weight management does not end when a trial ends. In STEP 5, adults treated for 104 weeks lost 15.2% of baseline body weight on average, compared with 2.6% with placebo, and 77.1% reached at least 5% weight loss compared with 34.4% on placebo. Novo Nordisk's STEP 5 report supports continued benefit over two years in that study population.
These results are averages, not personal forecasts. Participants also received lifestyle intervention, and individual response, adverse effects, access, adherence, and other health conditions can alter outcomes. The withdrawal findings also make maintenance planning relevant, since stopping treatment may change the course of weight management.
Wegovy is not interchangeable with tirzepatide products. Adults comparing options can review general tirzepatide treatment information before discussing differences with a prescriber.
Who May Be a Candidate, and Who Should Avoid It
Eligibility begins with the FDA label, but it doesn't end with BMI. For chronic weight management, an adult may meet the labeled criteria with a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater plus at least one weight-related condition. The FDA also approves Wegovy for children ages 12 years and older with obesity, with diet and physical activity, but this article focuses on adults.
The cardiovascular indication is separate. It applies to adults with established cardiovascular disease and obesity or overweight. A clinician may review cardiovascular history, blood pressure, glucose, lipids, sleep, prior weight-management efforts, current medicines, eating patterns, and other conditions before considering treatment.
Contraindications and cautions
Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma, a specific thyroid cancer, or multiple endocrine neoplasia type 2, a hereditary endocrine-tumor syndrome. It should also be avoided after a serious hypersensitivity reaction to semaglutide or one of the product's ingredients. The FDA label advises discontinuing Wegovy when pregnancy is recognized and stopping it at least 2 months before a planned pregnancy.
Other issues require careful clinical review rather than automatic self-exclusion:
- Pancreatitis history: Prior or suspected pancreatitis warrants a careful discussion because severe, persistent abdominal pain can signal a serious problem.
- Gallbladder disease: Gallstones or inflammation may require evaluation if upper abdominal pain, fever, or jaundice develops.
- Gastroparesis or severe gastrointestinal disease: Delayed stomach emptying can make tolerability and safety more complicated.
- Diabetes treatment: Combining Wegovy with insulin or a sulfonylurea can increase hypoglycemia risk, meaning blood glucose may fall too low.
- Dehydration: Vomiting or diarrhea can contribute to volume depletion and kidney injury.
Mental health and weight can also influence one another without making the conditions identical. Adults who want broader context may find this resource on how depression affects weight useful. It doesn't replace an obesity-medicine evaluation, and it shouldn't be used to diagnose depression or determine medication eligibility.
Comparing Wegovy With Other GLP-1 and Incretin Medicines
Brand names can create confusion because several products share an active ingredient or act on related hormone pathways. Semaglutide and tirzepatide aren't the same medicine, and products with the same active ingredient aren't automatically interchangeable.
| Product | Active ingredient | Mechanism class | FDA-approved indication | Formulation | Maximum labeled dose |
|---|---|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 receptor agonist | Chronic weight management, plus cardiovascular risk reduction in qualifying adults | Once-weekly injection | 2.4 mg |
| Ozempic | Semaglutide | GLP-1 receptor agonist | Type 2 diabetes and certain cardiovascular or kidney-risk indications under its own label | Once-weekly injection | 2 mg |
| Rybelsus | Semaglutide | GLP-1 receptor agonist | Type 2 diabetes | Oral tablet | 14 mg |
| Zepbound | Tirzepatide | GIP and GLP-1 receptor agonist | Chronic weight management and obstructive sleep apnea in qualifying adults under its own label | Once-weekly injection | 15 mg |
| Mounjaro | Tirzepatide | GIP and GLP-1 receptor agonist | Type 2 diabetes | Once-weekly injection | 15 mg |
The table is descriptive, not a ranking. Each product has its own FDA prescribing information, contraindications, titration schedule, administration instructions, and evidence base. A diabetes-labeled dose shouldn't be treated as a weight-management dose, and one brand shouldn't be substituted for another because the names or numbers appear similar.
Compounded or counterfeit semaglutide and tirzepatide create additional risks involving product identity, concentration, storage, sterility, and labeling. FDA safety communications should guide any concern about compounded GLP-1 medicines, rather than social-media claims or informal dosing comparisons.
Sleep-related symptoms can also complicate weight-management decisions. A practical executive sleep apnea guide may help explain why sleep evaluation belongs in a broader health discussion, but it doesn't determine which medication is appropriate. Switching between products requires a licensed prescriber who can review current therapy, risks, and the exact FDA label.
Side Effects, Safety Signals, and Routine Monitoring
The most common adverse effects are gastrointestinal. Nausea, vomiting, diarrhea, constipation, and abdominal pain can occur, especially while the dose is being increased. The labeled escalation uses steps separated by 4 weeks, which can improve tolerability for some people, but symptoms may still occur and the highest labeled dose isn't automatically the best dose for every patient.
Routine follow-up should ask practical questions. Is the person keeping fluids down? Are bowel movements changing? Is abdominal pain mild and passing, or severe and persistent? Has the person started another medicine, become pregnant, developed an illness, or changed diabetes treatment? Those details can change the clinical response.
Common symptoms versus urgent signals
| Situation | What it can mean | Appropriate next step |
|---|---|---|
| Mild nausea or temporary bowel changes | A common tolerability issue | Contact the prescribing clinician if it persists or interferes with eating and drinking |
| Repeated vomiting or inability to maintain fluids | Risk of dehydration and kidney complications | Seek prompt medical evaluation |
| Severe, persistent abdominal pain, especially with vomiting | Possible pancreatitis or another urgent abdominal problem | Seek urgent care |
| Upper abdominal pain with fever or yellowing of the skin | Possible gallbladder or liver-related concern | Seek prompt medical evaluation |
| New neck lump, persistent hoarseness, or trouble swallowing | A symptom that requires evaluation | Contact a clinician promptly |
| Vision changes, fainting, or severe weakness | Potentially serious medical issue | Seek urgent evaluation |
The label includes a boxed warning about thyroid C-cell tumors observed in rodents. Whether Wegovy causes medullary thyroid carcinoma in humans isn't established, but the personal and family history contraindication remains clinically important. Other safety concerns include pancreatitis, gallbladder disease, severe gastrointestinal reactions, hypoglycemia when combined with insulin or sulfonylureas, and acute kidney injury related to dehydration.
A clinician may review baseline and periodic weight, blood pressure, heart rate, kidney function, electrolytes, and glucose measures. Hemoglobin A1c, a longer-term blood-glucose marker, may be relevant for a person with diabetes. Pregnancy status may also matter when clinically applicable.
A clearly labeled composite example
Hypothetical composite, not an Empire patient: An adult reports nausea after a dose escalation. The prescriber confirms the exact product, reviews hydration and symptom severity, considers other causes, checks the current label, and may hold or delay escalation rather than assuming the highest dose is necessary.
The example doesn't provide a dosing instruction. It illustrates why patients should report symptoms instead of changing, skipping, or accelerating doses on their own.
Watch this patient-education video for general context, then rely on the current prescribing information and direct clinical guidance for decisions.
Sustaining Weight Management After Starting Wegovy
“What happens after Wegovy works, becomes harder to tolerate, or is stopped?” belongs in the treatment discussion from the beginning. In STEP 5, adults receiving Wegovy for 104 weeks maintained an average reduction of 15.2% of baseline body weight, compared with 2.6% with placebo. The trial report shows why results should be interpreted alongside the length of treatment and follow-up, rather than as a promise of permanent change.
Discontinuation raises a separate question. A systematic review found that weight commonly returns after weight-management medicines are stopped. Newer medicines such as semaglutide and tirzepatide were associated with faster average regain, with projections suggesting a return toward baseline over time. Another analysis estimated that 50% of initial weight loss was regained by about 7.5 months after stopping semaglutide or tirzepatide. The review of post-discontinuation weight regain also emphasizes that individual responses differ.
Medication can lower appetite signaling while it is active. It does not automatically build eating routines, preserve muscle, improve sleep, or address another condition affecting weight. A maintenance plan may include:
- Nutrition support: Regular meals and adequate protein give the clinician and patient a basis for discussing food quality, medication tolerance, and lean-mass preservation. Additional weight-loss guidance and nutrition support may help organize those conversations.
- Strength activity: Resistance training can support physical function and muscle preservation. This overview of building muscle while on GLP-1s provides general exercise context, not an individualized program.
- Sleep and stress care: Sleep disruption and chronic stress can affect appetite, energy, and adherence, so both deserve direct discussion.
- Ongoing measurement: Weight, waist circumference, blood pressure, glucose, lipids, and other laboratory measures may be followed according to a person's conditions.
- A transition plan: If symptoms, access, pregnancy, medical changes, or preference lead to discontinuation, the prescriber can discuss monitoring or another approved approach.
Regain is not a moral failure. It can reflect the return of biological appetite pressure after medication withdrawal, and available evidence shows substantial variation. NIDDK guidance supports individualized care combining nutrition, activity, behavior, and medical follow-up.
Cost, Coverage, and Practical Questions
Wegovy access depends on the prescription, the dispensing pharmacy, insurance rules, and the indication being used. Weight-management coverage can differ from coverage for the cardiovascular risk-reduction indication, and prior authorization may require documentation of eligibility and medical need. Empire Medical Wellness is a private-pay practice and doesn't bill insurance directly. Its current standard appointment fees are $350 for a 50-minute initial evaluation and $225 for a 25-minute follow-up, with an itemized receipt available through the patient portal.
| Item | What to expect | Patient action |
|---|---|---|
| Medical evaluation | A clinician reviews health history, medicines, goals, risks, and eligibility | Bring medication lists, prior weight history, and relevant laboratory or cardiovascular information |
| Insurance coverage | Rules may differ by plan and indication; approval isn't guaranteed | Ask the insurer about Wegovy coverage and prior authorization requirements |
| Private-pay care | The visit and medication are separate costs | Request an itemized receipt and ask the clinician what is included in follow-up |
| Medication supply | Wegovy is a prescription product that must come from an appropriate dispensing channel | Confirm the exact product, label, storage instructions, and refill process |
| Ongoing monitoring | Long-term care may involve symptom review, measurements, and relevant laboratory testing | Keep follow-up appointments and report concerning symptoms promptly |
Practical questions adults often ask
Is Wegovy permanent? It may be prescribed as long-term treatment, but duration depends on response, tolerability, medical indication, access, and shared decision-making. The possibility of regain after stopping should be discussed before treatment begins.
What if a dose is missed? Don't create a replacement schedule from online advice. Check the current Medication Guide and contact the prescribing clinician or pharmacist, especially if more than one dose was missed.
Can alcohol be used? Alcohol can worsen nausea, dehydration, impaired judgment, or blood-glucose problems for some people. Discuss personal risks with the prescriber rather than assuming it is harmless.
What about surgery? Tell the surgical and anesthesia teams that you use Wegovy. They can provide product-specific instructions based on aspiration risk, the procedure, symptoms, and current guidance.
Can someone switch medicines? Semaglutide and tirzepatide products aren't interchangeable. Brand, formulation, dose, contraindications, and follow-up must be reviewed by a licensed prescriber.
Empire Medical Wellness offers private-pay physician-led obesity care that may include medical and metabolic assessment, medication evaluation when clinically appropriate, monitoring, and long-term maintenance planning. Visit Empire Medical Wellness to review the practice's obesity-care options and request information about an evaluation.
Byline: Empire Medical Wellness Editorial Team
Published: September 5, 2026
Updated: September 5, 2026
Sources
- FDA Wegovy prescribing information
- FDA Wegovy label and controlled-trial evidence
- FDA approval announcement and STEP 1 evidence
- Review of weight regain after medication discontinuation
Empire Medical Wellness provides physician-led obesity care for adults seeking thoughtful evaluation and ongoing medical follow-up. This article is educational and isn't personal medical advice.